Welcome to our dedicated page for Pheton Holdings news (Ticker: PTHL), a resource for investors and traders seeking the latest updates and insights on Pheton Holdings stock.
Pheton Holdings Ltd (PTHL) is a healthcare solution provider that focuses on treatment planning systems for brachytherapy and related products and services. This news page aggregates company announcements and market disclosures so readers can follow how Pheton’s business and corporate identity have evolved over time.
News about Pheton has highlighted its role in developing Beijing Feitian’s Treatment Planning System, a brachytherapy treatment planning system used outside the United States to support safe and effective radiation therapy for cancer patients. Company press releases also describe efforts to position its products and services across multiple malignant tumor applications.
Recent announcements provide insight into Pheton’s broader healthcare technology strategy. The company has reported entering into stock purchase agreements to acquire equity interests in healthcare technology businesses, including a majority interest in iTonic Corporation, a U.S.-based integrated home health AI company that combines AI, medical device automation, and access to clinical expertise to support continuity of care in the home. Pheton has characterized this acquisition as a step toward expanding into the home health market and integrating a home health platform that supports medication dispensing, virtual care, patient monitoring, and care coordination.
Corporate news has also covered Pheton’s initial public offering on the Nasdaq Capital Market, its status as a foreign private issuer, and subsequent updates on listing compliance matters such as a Nasdaq notification regarding the minimum bid price requirement. Additional releases address corporate governance topics, including responses to market rumors and statements about transparency and shareholder communication.
One of the most significant recent developments is Pheton’s announcement that it will change its corporate name to iTonic Holdings Ltd and its Nasdaq ticker symbol from "PTHL" to "ITOC." The company has stated that this change reflects a new business strategy and future development plans. Investors and observers can use this news page to review historical press releases under the PTHL symbol and understand the context behind the transition to the iTonic identity.
Pheton Holdings Ltd (PTHL) announced on January 13, 2026 that it will change its corporate name to iTonic Holdings Ltd and its Nasdaq ticker symbol from PTHL to ITOC. The company said the changes reflect its new business strategy and future development plans. The Corporate Events are expected to become effective upon the commencement of trading on the Nasdaq Capital Market on January 16, 2026 (U.S. Eastern Time), at which time the company’s Class A ordinary shares will cease trading under PTHL and begin trading under ITOC.
Pheton Holdings (NASDAQ: PTHL) completed the acquisition of 51% of iTonic Corporation, a U.S. home-health AI company, with closing on November 25, 2025. Consideration includes 4,000,000 newly issued Class A shares subject to performance milestones and warrants to buy up to 3,000,000 Class A shares at an exercise price of $3.10, exercisable in tranches tied to quarterly or annual SPA milestones. The deal was first reported on Form 6-K on August 29, 2025. Management says the acquisition expands Pheton’s U.S. footprint and adds iTonic’s AI-driven home health platform to its product mix, aiming to enhance continuity of care and patient outcomes.
Pheton Holdings (NASDAQ: PTHL) disclosed receipt of a Nasdaq notice dated October 20, 2025, that its Class A ordinary shares no longer meet the Nasdaq minimum bid price requirement of $1.00 under Rule 5550(a)(2) based on the last 30 consecutive business days.
Nasdaq granted an initial 180-calendar-day compliance period ending April 20, 2026 to regain compliance. The company may be eligible for a second 180-day period if it meets market-value and other initial listing requirements (except the bid price) and provides notice to cure, potentially by effecting a reverse stock split. The company is evaluating options and intends to seek timely compliance but provided no assurance it will succeed.
Pheton Holdings (NASDAQ:PTHL), a healthcare solution provider specializing in brachytherapy treatment planning systems, has issued an official statement addressing recent market volatility and misleading rumors. The company's stock experienced a significant decline following a speculative article published by The Bear Cave on July 29, 2025.
The company categorically denies any involvement in stock price manipulation or rumors regarding a potential acquisition by Gilead Sciences. Pheton confirms it has had no contact with Gilead and plans to engage with Nasdaq and regulatory bodies to address the situation. Management emphasizes its commitment to transparency and maintaining strong corporate governance standards.
Pheton Holdings , a healthcare solution provider specializing in brachytherapy treatment planning systems, has successfully closed its initial public offering (IPO). The company offered 2,250,000 Class A ordinary shares at $4.00 per share, raising gross proceeds of $9 million. Pheton's shares began trading on the Nasdaq Capital Market under the symbol 'PTHL' on September 5, 2024.
The underwriters have a 45-day option to purchase up to 337,500 additional shares. Proceeds will fund research and development, technology upgrades, market expansion, and operational improvements. CATHAY SECURITIES, INC. led the underwriting, with Dominari Securities as co-underwriter.
Pheton Holdings (PTHL), a healthcare solution provider specializing in treatment planning systems for brachytherapy, announced the pricing of its initial public offering (IPO). The IPO comprises 2,250,000 Class A ordinary shares priced at $4.00 per share, totaling $9 million in gross proceeds before deductions. Underwriters have a 45-day option to purchase an additional 337,500 shares at the IPO price, minus underwriting discounts. Trading is set to commence on the Nasdaq Capital Market on September 5, 2024, under the ticker symbol 'PTHL'. The IPO is expected to close on September 6, 2024, pending customary closing conditions. CATHAY SECURITIES and Dominari Securities are leading the underwriting process. Legal counsel includes Hunter Taubman Fischer & Li for the company and The Crone Law Group P.C. for the underwriters.
FAQ
What is the current stock price of Pheton Holdings (PTHL)?
What is the market cap of Pheton Holdings (PTHL)?
